Pfizer Inc.

The President is scheduled to sign an Executive Order on Monday to upend the entire pharmaceutical industry.

A cooling of trade tensions between the world's two biggest economies sends U.S. stocks soaring Monday.

Stocks are back in the red as more companies articulate the impact of President Trump's tariffs on their bottom line.

The tech giant's earnings report is one of hundreds due this week, the busiest week in an earnings season driven by volatility.

Stocks are looking to extend their strongest weekly rally since late 2023.

Taylor Swift is back for another Super Bowl. Like her or not, she's having an impact.

Bond markets are back in focus as the Federal Reserve begins its two day policy meeting in Washington.

Stocks finish down for the week amid the ongoing selloff in Treasury bonds.

Another leg higher in Treasury bond yields is muting stock gains heading into a busy earnings session on Wall Street.

Here are the stocks making the biggest market moves midday.

Wall Street will navigate a busy Tuesday session of earnings and data with updates from AMD and Microsoft due after the closing bell.

Stocks rallied after an encouraging PCE inflation print, but not every company is a winner today.

Pfizer is looking to challenge leaders Eli Lilly and Novo Nordisk in the fast-growing market for weight loss drugs.

Stocks could face a stern test to their longest winning streak in three years with today's June inflation report.

Nvidia shares will begin trading on a split-adjusted basis Monday, but remain the world's third most-valuable stock.

This is what could happen next to Snowflake shares.

Stocks ended mixed Wednesday following a rollercoaster session highlighted by a hawkish Federal Reserve policy meeting.

In addition to economic and earnings news, inflation and geopolitical worries will have roles to play.

Analysts' stock picks include retail, consumer, and healthcare stocks.

Let's run down the list of indicators and see what they're telling us.

These three healthcare names can provide strong dividend yields as healthcare demands outpace GDP growth.

Let's see why these health-care stocks moved higher yesterday and how to I'd approach them.

Penny stocks are important to watch because they indicate speculative activity.

Monday appears an exhibition game as earnings blitz looms, Scott Bessent makes the rounds, and JP Morgan states ... the obvious.

This biotech/biopharma name is on the top of my shopping list right now.

Here's what the market desperately needs right now and my main strategy for navigating it.

Stocks fell on Monday, but the damage was worst among the Mag 7 stocks. Otherwise, there was a bit of rotation. What's next?

These three high-yield names can secure dividend payouts for investors looking to achieve passive income.

We might see a turnaround on Tuesday, but it's unlikely that there's much of a rally to be had right now.

Making the investment case for these three small- and mid-cap names as volatility is likely to continue.

Here's how I'm lining up a potentially lucrative trade on an oncology-focused stock trading below $10.

Rotational action is picking up traction as the Mag 7 names struggle. Here are two names that could benefit.

Is it okay to get back in the water? Wait, who's that guy with the hockey mask?

Wall Street has once gain turned into 'Penny Lane' and this speculation in penny stocks isn't normal or healthy. Let's break it all down and take a look at Pfizer, Johnson & Johnson and more.

A look at market sentiment, as well as your questions.

It's highly unusual for a market that's been up so much to tumble into year-end. So, let's take a look at the indicators. Plus, META, CTRA, PFE, PR, AMD, EWQ, TLT, EOG, and CCJ.

It's a choppy market with bad breadth. We'll also look at OIH, LIT, BKSY, PFE, CRH, AVGO, and NOW.

As the Fed struggles to wrangle interest rates, big-ticket purchases that require financing will suffer.

The investment firm's analysts share their views about the precious metal.

UnitedHealth, still reeling from the murder of one of its top executives, is reportedly facing a Department of Justice investigation.

The federal agency has opted to make a drastic decision during a critical time of the year.